GlassScriptPhysician profile
Mary Beth Doyle
NPI 1841352655
$1,883.12
in general payments reported to CMS, 2019-2025
19 companies · $402 in 2025
The $402 reported for 2025 was more than what 90% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $95.23 · 2021: $205 · 2022: $282 · 2023: $281 · 2024: $380 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,062.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $651.91 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $224.65 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $199.88 | 2019-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $177.88 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Glaxosmithkline, LLC. | $89.32 | 2019-2024 | Bexsero |
| Sobi, INC | $84.97 | 2019-2022 | |
| Pfizer INC. | $70.43 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $68.41 | 2024-2025 | |
| Tris Pharma INC | $51.08 | 2019-2025 | Dyanavel Xr |
| Cranial Technologies, INC | $49.22 | 2024-2025 | Doc Band |
| Neurelis, INC. | $48.04 | 2021-2022 | |
| Vertical Pharmaceuticals, LLC | $41.78 | 2019-2024 | Relexxii |
| Ultragenyx Pharmaceutical INC. | $24.27 | 2024 | Crysvita |
| Abbott Laboratories | $20.46 | 2025 | Id Now Instrument |
| Aytu Biopharma, INC. | $18.93 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $17.37 | 2025 | Jornay Pm |
| Dermira, INC. | $15.50 | 2020 | |
| Arbor Pharmaceuticals, INC. | $15.35 | 2022 | |
| Supernus Pharmaceuticals, INC. | $13.67 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Beth Doyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.